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Abstract
There is substantial evidence which implicates α-synuclein and its ability to aggregate and bind vesicle membranes as critical factors in the
development of Parkinson's disease. In order to investigate the interaction between α-synuclein wild type (Wt) and its familial mutants, A53T and
A30P with lipid membranes, we developed a novel lipid binding assay using surface enhanced laser desorption/ionisation-time of flight-mass
spectrometry (SELDI-TOF MS). Wt and A53T exhibited similar lipid binding profiles; monomeric species and dimers bound with high relative
affinity to the lipid surface, the latter of which exhibited preferential binding. Wt and A53T trimers and tetramers were also detected on the lipid
surface. A30P exhibited a unique lipid binding profile; monomeric A30P bound with a low relative affinity, however, the dimeric species of A30P
exhibited a higher binding ability. Larger order A30P oligomers were not detected on the lipid surface. Tapping mode atomic force microscopy
(AFM) imaging was conducted to further examine the α-synuclein–lipid interaction. AFM analysis revealed Wt and its familial mutants can
penetrate lipid membranes or disrupt the lipid and bind the hydrophobic alkyl self-assembled monolayer (SAM) used to form the lipid layer. The
profile of these studied proteins revealed the presence of ‘small features’ consistent with the presence of monomeric and dimeric forms of the
protein. These data collectively indicate that the dimeric species of Wt and its mutants can bind and cause membrane perturbations.
© 2008 Elsevier B.V. All rights reserved.Keywords: Parkinson's disease; α-Synuclein; Lipid membrane; SELDI-TOF MS; AFM1. Introduction
Parkinson's disease (PD) is a neurodegenerative disorder,
which is characterized by a loss of dopaminergic neurons in the
substantia nigra, resulting in resting tremors, slow movement
and rigidity [1]. Prevalence rates of PD are ∼1% amongst
individuals aged between 65–69 and increase in those aged
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doi:10.1016/j.bbamem.2008.01.012α-Synuclein is a 14.5 kDa presynaptic protein believed to
play an important role in the pathogenesis of PD [3]. Evidence
supporting this hypothesis includes the finding that Lewy
bodies, cytostolic inclusions characteristic of PD, consist largely
of fibrillar α-synuclein [4]; triplication or point mutations (A53T
and A30P) in the α-synuclein gene have also been linked to PD
[5–7]. Furthermore, expression of human α-synuclein in trans-
genic mice produces a PD phenotype, which is both age and
dose-dependent [8].
The mechanisms by which α-synuclein induces toxicity in
PD pathogenesis remain unclear, although there is substantial
evidence which implicates lipid membrane binding and the
ability of α-synuclein to aggregate as important factors. Fibril
formation maybe initiated by a number of factors; (i) misfolded
intermediates, which exhibit non-polar patches, binding to other
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(ii) increased protein concentration arising from triplication of
the α-synuclein gene [5], (iii) exposure to oxidative factors [10],
or (iv) interactions with lipids [11]. Point mutations can also
accelerate α-synuclein fibrilisation, supporting the premise that
this event may be a critical factor in disease pathogenesis [9,12].
The process of fibril formation is often preceded by oligomeric
intermediates termed protofibrils, these are consumed as more
stable fibrils are formed. It is these intermediate products, rather
than the fibrils, which are believed to be the toxic species re-
sponsible for the neurodegeneration associated with the disease
[13].
The α-synuclein–membrane interaction is considered to be a
potential cytotoxic event, resulting in the permeabilisation of
the cell membrane [14]. Upon interactions with lipid membranes,
α-synuclein undergoes a conformational change from a random
coil to an α-helical structure [15]. The N-terminus of α-synuclein
contains a series of 11 amino acid repeats with a conserved hexa-
meric motif (KTKEGV), which is characteristic of lipid binding
α-helical domains of apolipoproteins and facilitates this inducible
structural change. The acidic C-terminus of the protein, however,
remains essentially unstructured [15–17]. Examination of the
familial point mutations revealed that A53T binds to membranes
with a similar affinity to α-synuclein wild type (Wt), whilst A30P
exhibits weaker binding [18–21]. Interestingly, it is the inter-
mediate oligomers which bind to membranes with a high affinity
and causemore rapid permeabilisation of cell membranes than the
monomeric species [13,14,22]. Ascertaining the precise oligo-
meric species that associate and disrupt membranes is thus critical
for further understanding of the pathogenesis of the disease pro-
cess. Towards this aim, we developed a novel assay using surface
enhanced laser desorption/ionisation-time of flight-mass spectro-
metry (SELDI-TOF MS) to measure the ability of α-synuclein
Wt, A53T and A30P to bind “on-chip” to synthetic lipid mem-
branes. The α-synuclein–lipid interaction was further examined
by atomic force microscopy (AFM) imaging.
2. Materials and methods
2.1. Expression and purification of α-synuclein Wt, A30P and A53T
α-Synuclein Wt and its mutants were prepared as described by Cappai et al.
[23]. Briefly, human α-synuclein Wt was cloned into pRSETB (Invitrogen, Carls-
bad, CA, USA) and expressed in Escherichia coli, BL21 (DE3). The Quikchange
mutagenesis kit (Stratagene, La Jolla, CA, USA) was used to generate A30P and
A53T. Purification was performed as previously described [23].
2.2. Preparation of α-synuclein Wt, A30P and A53T for functional
studies
α-Synuclein Wt, A30P and A53T were initially filtered (0.2 μm Minisart
RC4 filters, Sartorius, Goettingen, DEU) to remove pre-formed aggregates and
prepared in 10 mM phosphate buffer, pH 7.4 (PB) at a final concentration of
200 μM.
2.3. Preparation of vesicles
Equal amounts of 1-palmitoyl-2-oeoyl-sn-glycero-3 [phospho-L-serine]
(POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (Avanti
Polar Lipids, Inc., Alabaster, AL, USA) (16 mg) were dissolved in 2 ml ofethanol-free chloroform. The solvent was evaporated and lipids were re-
suspended in 1 ml of PB by mixing (200 rpm) with glass beads for 1 h at 37 °C.
The lipids were sonicated for 15 min and subjected to several freeze thaw cycles
in liquid nitrogen. The lipids were finally passed through a 0.05 μM filter
(Millipore, Bedford, MA, USA) in an Avanti “mini extruder” apparatus until the
solution was translucent.
2.4. Formation of a lipid monolayer on H50 ProteinChip arrays
Hydrophobic H50 ProteinChip arrays (Bio-Rad Laboratories, CA, USA)
with functional C8 groups were placed in a humidity chamber. Each spot was
loaded with 5 μl of CHAPS (30 mg/ml), which was immediately wicked off,
followed by three 2 min washes with 5 μl of PB on a shaking platform. The
POPC/POPS mixture or PB (5 μl) was applied to each spot and incubated for 2 h
at 37 °C. Arrays were washed twice with PB to remove unbound lipid.
2.5. Protein binding to the lipid coated H50 ProteinChip arrays
BSA (Sigma Aldrich, Munich, DEU), melitin (Sigma Aldrich), α-synuclein
Wt, A30P or A53T (5 μl, 50 μM) were loaded onto spots coated with either the
POPC/POPS lipid mixture or PB and incubated for 5 min with agitation. Arrays
were washed twice with PB for 2 min, followed by two 1 min washes with 1 mM
HEPES, pH 7.2. The arrays were air dried and l μl of 50% saturated sinapinic
acid in 50% (v/v) acetonitrile, 0.5% trifluoroacetic acid was applied onto each
spot twice, arrays were air dried between each application. Sinapinic acid was
chosen since high mass proteins were to be assessed. Arrays were finally ana-
lysed by SELDI-TOF MS (PBSIIc) and subsequent spectra was examined using
ProteinChip software® (Bio-Rad Laboratories). Every 5th position on the spot
was scanned, 5 transients per position (65 total) were collected.
2.6. SELDI-TOF MS analysis of α-synuclein Wt, A53T and A30P on
NP20 ProteinChip arrays
1 μl of α-synuclein Wt, A30P and A53T was loaded onto spots of a NP20
ProteinChip array (Bio-Rad Laboratories) and air dried. Matrix was prepared
and applied as described above. Arrays were analysed by SELDI-TOF MS and
spectra was examined using ProteinChip software®.
2.7. Preparation of samples for AFM Imaging
The surfaces used were prepared via a 3 step procedure. Glass slides were
cleaned with piranha solution (sulphuric acid: H2O2 (3:1, v:v) for 1 h and then
rinsed with MilliQ water. A mask was applied to the surface in order to generate
a spherical surface on the glass substrate allowing improved localization of the
sample. 5 nm of chromium (Proscitech, Thuringowa, QLD, AU) and 50 nm of
gold (Proscitech) were sequentially sputter coated on the substrates with an
EMITECH K575 sputter-coater apparatus (Emitech Ltd., Ashford Kent, UK).
Finally, a SAM of octadecanethiol was organized on the gold spherical surface
of the substrate by leaving the substrate in a 1 mM solution overnight. The
samples were then ready for lipid adsorption. The contact angle for the SAM
was measured at 108°±4° with a Dataphysics Contact Angle System OCA 15
plus, at ambient temperature with a CCD camera (Teli) and the computer soft-
ware ‘SCA 20’.
2.8. Formation of a lipid monolayer
The AFM imaging samples were placed in a humidity chamber. Each slide
was loaded with 10 μl of CHAPS (30 mg/ml), which was immediately wicked
off, followed by five 2 min washes with 10 μl of PB. The POPC/POPS mixture
or PB (10 μl) was applied to each spot and incubated for 2 h at 37 °C. Slides
were washed with PB three times to remove unbound lipid.
2.9. Protein binding to the lipid coated surfaces
BSA, melitin, α-synuclein Wt, A30P or A53T (10 μl, 50 μM) were loaded
onto slides coated with the POPC/POPS lipid mixture or PB and incubated for
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washes with 1 mM HEPES, pH 7.2. The slides were air dried in preparation for
AFM analysis [13].
2.10. Tapping mode AFM imaging
Tapping mode imaging was conducted with a Dimension 3100 Atomic
Force Microscope (Veeco Instruments, Santa Barbara, CA, USA) using a
Nanoscope III controller and the program Veeco DI v5.18 for data treatment.
Budget Sensors cantilevers (Sofia, BGR) with a 300 kHz resonant frequency and
spring constant k=40 N/m were used in the analysis. Interpretation was made
using the WsXM 4.0v7.5 program from Nanotec Electronica (Madrid, ESP)
[24]. The scan rates were set between 0.5–1 Hz, depending on the scan size and
the samples per line were set to 512 for 512 lines.
The protein average sizes were determined from 6–10 scanned areas on each
sample, up to 4 samples were prepared for each protein.3. Results
3.1. Oligomeric profiles of α-synuclein Wt, A53T and A30P on
NP20 arrays
The oligomeric content of freshly prepared α-synuclein Wt,
A53T and A30P was initially assessed on NP20 arrays. Mo-
nomers and several oligomeric species, including dimers, trimers,
tetramers and pentamers, were clearly detected (Fig. 1). Matrix
adducts were detected as noted by the presence of a minor peak
with a mass shift of ∼224 Da. The area under the curve (AUC)
values was subsequently assessed. Themonomers were identified
to be the most abundant species for α-synuclein Wt, A53T
and A30P, followed by dimers and the remaining larger order
oligomers.Fig. 1. SELDI-TOFMS profiles of α-synuclein Wt, A53T and A30P on NP20 arrays.
then subjected to SELDI-TOF MS. Resulting spectra analysed in ProteinChip softw
intensities and molecular weights are shown on the Y and X axis, respectively.3.2. Oligomeric profiles of α-synuclein Wt, A53T and A30P on
lipid coated H50 arrays
In order to identify the oligomeric species which bind to lipid
membranes, a novel solid phase lipid binding assay was de-
veloped. Lipid monolayers were formed on H50 ProteinChip
arrays using small unilamellar vesicles prepared from a mixture
of extruded and sonicated phospho-L-serine/phosphocholine.
The ability to create a lipid monolayer on the chip surface was
initially assayed by examining the amount of (i) non-specific
binding of bovine serum albumin (BSA), which binds with a
higher affinity to hydrophobic surfaces in the absence of lipid
[25] and (ii) specific binding of melitin, a membranolytic pep-
tide [26]. BSA bound to the hydrophobic surface with an AUC
value of 2060. In the presence of lipid; BSA binding decreased
∼2 fold with a signal to noise value of 1022 (Fig. 2). Melitin
was shown to bind with a∼10 fold increase in signal to the chip
surface in the presence of lipid with an AUC value of 506
in comparison to an AUC value of 48 in the absence of lipid
(Fig. 2). These control experiments demonstrated that we were
able to specifically capture and analyse a lipid binding protein
using this system.
Upon establishment of the methodology, we assessed the
lipid binding ability of Wt α-synuclein, A53T and A30P. Wt α-
synuclein monomer bound specifically to the lipid surface with
an AUC value of 8663 compared to 145 in the absence of lipid.
A53Tmonomer also bound specifically to the lipid coated arrays
in a similar manner to Wt α-synuclein, an AUC value of 8691
was recorded. A30P monomer exhibited a decreased binding
with an AUC value of 1198 being recorded (Fig. 3). AssessmentSamples were loaded onto arrays and air dried. SPAwas applied to each spot and
are, revealed the presence of monomeric and several oligomeric species. Peak
Fig. 3. SELDI-TOF MS profiles of α-synuclein Wt, A53T and A30P on lipid
coated H50 arrays. α-Synuclein Wt or its mutants were loaded on spots coated
with either a POPC/POPS lipid monolayer or PB and incubated for 5 min. Spots
were washed to remove non-specifically bound components. SPAwas applied to
each spot and arrays were subsequently subjected to SELDI-TOF MS. Analysis
of resulting spectra revealed that the Wt (panel a) and A53T mutant (panel b)
bound to the surface with a high affinity and exhibited a similar binding pat-
tern, with the dimeric species exhibiting preferential binding. Interestingly, the
A30P mutant exhibited weaker binding (panel c); however, again the dimeric
species exhibited preferential binding in comparison to the monomer. AUC
values of α-synuclein Wt (panel d), A53T (panel e) and A30P (panel f ) on lipid
coated H50 arrays and H50 arrays alone are also displayed, demonstrating the
specific binding patterns of the monomers and oligomers.
Fig. 2. SELDI-TOF MS profiles of melitin and BSA on lipid coated H50 arrays
(panel a) and H50 arrays alone (panel b). Melitin or BSA was loaded on spots
coated with either a POPC/POPS lipid monolayer or 10 mM phosphate buffer,
pH 7.4 (PB) alone and incubated for 5 min. Spots were washed to remove non-
specifically bound components. SPA was applied to each spot and arrays were
subsequently subjected to SELDI-TOF MS. Analysis of resulting spectra
revealed that melitin binds with a higher affinity to the lipid coated surface,
whilst BSA exhibits higher affinity to hydrophobic surface in the absence of the
lipid.
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mers, trimers and tetramers on the lipid surface. The dimer
exhibited a higher signal as shown by the AUC, which implies a
preferential binding and a higher affinity for the dimer over
monomer (AUC value of 12663) (Fig. 3). A53T exhibited an
oligomeric lipid binding profile similar toWt α-synuclein, again
dimers, trimers and tetramers were detected on the lipid surface.
Dimers exhibited the highest binding ability (AUC value of
12165), preferentially binding to the lipid surface in comparison
to the monomer (Fig. 3). Interestingly, A30P exhibited a unique
oligomeric lipid binding profile. A30P dimeric species were
detected on the lipid surface, however, larger order A30P oli-
gomers were not identified. The A30P mutant dimers exhibited
∼7 fold higher AUC value (8986) than the monomeric species
(Fig. 3).
3.3. Tapping mode AFM imaging
In order to further examine the ability of Wt α-synuclein,
A53T and A30P to interact with lipid membranes AFM analysis
was conducted. Lipid monolayers were initially created on
a hydrophobic surface of an octadecanethiol SAM. The affinity
of sulfur atoms in alkanethiol molecules towards gold sur-
faces allows SAM formation on the metallic surface [25,27,28].
Changing the functionality of the alkanethiols and their chain
length gives surfaces with tunable properties [28]. The hydro-
phobicity of long chain alkylthiols was used to adsorb a mo-
nolayer of lipids on the substrate.
Fig. 4a shows the plain gold surface with the self-assembled
monolayer (SAM) (RMS roughness of 1 nm, average height of
Fig. 4. AFM image of a gold-SAM substrate (panel a), lipid monolayer on a gold-
SAM substrate (panel b) and profile studies of the lipid monolayer (panel c). Glass
slides were initially cleaned with piranha solution and sequentially sputter coated
with chromium and gold. A SAM of octadecanethiol was organized on the gold
surface followed by incubationswith either PBor POPC/POPS to create a synthetic
lipid monolayer. The lipid layer was comparatively smooth, small areas with no
lipid allowed the thickness of the lipid film to be ascertained.
Fig. 5. AFM image of α-synuclein Wt binding to a lipid monolayer. Addition of
α-synuclein resulted in a clear disruption of the lipid layer (panel a). A closer
view of the associated proteins showed a characteristic pattern of lipid disruption
surrounding the embedded protein (panel b). Typical profiles of the associated
proteins showed the presence of monomers and oligomers (panels c and d,
respectively).
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tively the smooth lipid monolayer adsorbed on the substrate
(RMS roughness of 1.5–2 nm, average height of 5.6 nm on a
3 μm×3 μm scan, Fig. 4b). A profile study of the lipid mono-
layer on the SAM substrate shows small areas with no lipid,
allowing the measurement of the thickness of the lipid film
(Fig. 4c). The average height of the lipid layer measured was
determined to be thicker than a long chain lipid monolayer [29],
which is due to the (a) cumulative effect of gold, alkyl and lipid
roughness (b) tapping mode imaging (amplitude can create 1 nm
profile difference) (c) furthermore, a 1–1.5 nm error in height
can be generated due to the experimental calibration error.
The addition of Wt α-synuclein to the substrate resulted in a
clear disruption of the lipid surface surrounding the protein
(Fig. 5a). Interestingly, areas were detected which exhibited
significant disruption without the presence of protein. These are
believed to be areas where the protein was embedded into the
lipid layer and removed during the post binding washes sub-
sequently lifting off the surrounding lipid. In Fig. 4b, the lipid
monolayer itself presents some defects in its formation, ne-
vertheless the surface sizes of these defects are much smaller
than in the presence of the protein (order of magnitude: 10–20
times smaller). The lipid monolayer is therefore considered to
be rougher and patchy after treatment with Wt α-synuclein.
Further observations indicated that the protein still bound to the
lipid layer in fact appears to “push away” the lipid, disrupting
the cohesive forces of the monolayer. An interesting character-istic pattern of lipid disruption was identified to surround the
protein; disruption was generally limited to one direction, but
not surrounding the entire protein as relatively little lipid di-
sruption was observed in the adjacent flanking regions (Fig. 5b).
We cannot affirm if the protein is actually embedded in the lipid
layer or if it is binding directly to the SAM after lipid disruption.
Profile studies of the lipid associated proteins were subse-
quently conducted, however, since the chemical conformation
of these proteins on a surface has not been ascertained, the width
and height of the absorbed proteins is unknown. The mea-
surement of protein dimensions on the surfaces was averaged
out of 4–6 surfaces and 6–10 spots on each surface. In ac-
cordance with SELDI-TOF measurements, we consequently
concluded that the “small features”, which exhibited an average
size of 61–65 nm, were monomeric forms of the protein whilst
features double in size were probable dimeric forms of the
protein. We observed the same lipid monolayer disruption for
the putative monomers and dimers, except the size is roughly
doubled in the latter case (Fig. 5c and d, respectively).
It is important to note that the precision on Z scan axis versus
the X–Y scan directions is strongly dependent on the scanning
parameters, especially the scan size chosen for the sample
measurements. Scan sizes of 5–0.5 μm were initially performed
which showed large areas of lipid disruption associated with the
putative monomers and dimers. Smaller scans (200 nm) were
subsequently performed in order to more accurately assess the
sizes of the monomers/dimers, but have not been presented due
Fig. 6. AFM image of A53T binding to a lipid monolayer (panel a) and typical
profiles of the associated proteins, showing the presence of monomers and
oligomers (panels b and c, respectively).
Fig. 7. AFM image of A30P binding to a lipid monolayer (panel a) and typical
profiles of the associated proteins, showing the presence of monomers and
oligomers (panels b and c, respectively).
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stick to the tips interfering with data interpretation. Tip radius
(tip effects) may also complicate AFM imaging and interpreta-
tion of distances or sizes.
Upon assessment of the mutant proteins, we observed that
A53T and A30P were also able to bind the lipid monolayer and
exhibited a similar pattern of disruption to that of α-synucleinWt
(Fig. 6a). A profile study of A53T and A30P proteins associated
with the lipid layer revealed the presence of monomers identified
to be 46–51 nm and 35–42 nm in diameter, respectively (Figs. 6b
and 7b); dimers were also detected (Figs. 6c and 7c).We postulate
that the variation in AFM size measurements betweenWt and the
mutants is likely to be the result of conformational differences
between the proteins since (i) both A30P and A53T substitutions
have been shown to alter the conformation of α-synuclein [7,30]
and (ii) AFM is capable of resolving differences in length, dia-
meter and conformation (stiffness, aggregation, mode of adsorp-
tion to a substrate) between features [31].
Control experiments show that BSA embedded in the lipid
layer did not perturb the surface monolayer. The size of the
protein was ∼105 nm (89–118 nm) (Supplementary data).
Experiments conducted with melitin revealed total disruption of
the lipid monolayer, with small patches of lipid detected after
melitin adsorption.
4. Discussion
Common methods employed for the analysis of protein–lipid
interactions include (i) ultracentrifugation or size filtration
chromatography of vesicles exposed to the lipid binding pro-tein (ii) thin layer chromatography (iii) circular dichroism (CD)
spectroscopy and (iv) surface plasmon resonance (SPR) [17,
19,25]. Chromatography and ultracentrifugation require several
hours; during this period proteins can continue to aggregate
complicating data interpretation. CD spectroscopy reveals con-
formational changes to the protein which are induced upon
interactions with lipids [17]; however, quantitative analysis can
be difficult. Lipid binding affinities can be assessed by em-
ploying SPR, however, isolating the specific oligomers which
interact with the lipid membrane cannot be undertaken. As a
consequence of these limitations, we developed a novel SELDI-
TOFMS assay as a tool for determining the lipid binding profiles
of Wt α-synuclein, A53T and A30P with the aim of identifying
the key species involved in membrane binding/disruption.
During this assay vesicles are coated onto H50 ProteinChip
arrays via C8 functional groups creating a supported lipid mo-
nolayer. Proteins are subsequently applied to the array for 5 min
followed by washing to remove non-specifically bound com-
ponents. Proteins retained on the chip surface are then resolved
by TOF MS which displays the mass-to-charge value and signal
intensities of the individual proteins. In contrast to conventional
methodologies, this assay allows the rapid detection and relative
quantitation of oligomers, which are bound specifically and
directly to lipid membranes.
Employing the SELDI-TOF MS-lipid binding assay, we
identified that the monomeric species of Wt α-synuclein and
A53T bind with a similar ability to the lipid monolayer, whilst
A30P binds weakly. This is in agreement with several studies,
which have employed vesicle/lipid droplet binding assays com-
bined with ultracentrifugation, sucrose gradient centrifugation
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affect lipid binding whilst A30P inhibits but does not com-
pletely eliminate binding [18–22,32,33]. Reduced binding of
the A30P mutant could be explained by the fact that the proline
substitution is in the helical-membrane binding domain, poten-
tially creating a small break in the helix affecting the con-
formation and decreasing overall helicity [34].
Interestingly, the dimeric species of α-synuclein Wt, A53T
and A30P all bound with a high relative affinity and were iden-
tified to preferentially associate with the lipid surface in com-
parison to the monomeric species. The role of the dimer in lipid
binding has been previously examined by Cole et al. [22] who
employed chemical cross linking studies of α-synuclein Wt,
A53Tand A30P and revealed that principally dimers and trimers
associated with lipid droplets and cell membranes. Further to
this, Jo et al. [19] treated vesicles withα-synucleinWt and A30P
and revealed that the membrane bound fractions consisted only
of dimers. The amount ofWt dimer present in the membrane was
higher than the A30P, which is consistent with results herein.
Recently, Smith et al. [35] utilised SPR to investigate the
interaction of α-synuclein with lipid membranes as a function of
its aggregation state. Interestingly, this analysis revealed the
presence of a high affinity lipid binder which is an early com-
ponent from the amyloid aggregation pathway. There has been
some debate as to whether (i) the dimer is preferentially binding
to the lipid or (ii) the monomeric form of α-synuclein binds
to the membrane and subsequently forms dimers. To assess
these possibilities Jo et al. [19] measured the α-helicity of fresh
and aged α-synuclein upon binding to lipid vesicles, the fresh
batch of α-synuclein contained low dimeric content, whilst the
aged α-synuclein exhibited higher dimeric content. They iden-
tified that the aged sample exhibited higher α-helicity indicating
the dimer is preferentially binding. Based on these findings we
postulate that the dimer is in fact preferentially binding to the
lipid surface.
Examination of the higher order oligomers revealed the pre-
sence of Wt and A53T trimers and tetramers on the lipid surface,
however, no higher order A30P oligomers were detected. It is
important to note that SELDI-TOFMS, like otherMS techniques,
exhibits lower sensitivity in the higher mass range hence the lack
of higher order oligomers does not indicate their absence or failure
to bind lipid monolayers, but is a reflection of the limitation of the
assay under the described conditions.
AFM imaging analysis using in situ tapping mode was con-
ducted to further assess the α-synuclein–lipid interaction. Lipid
monolayers were assessed, in place of bilayers, to allow direct
comparisons with the SELDI-TOF MS-lipid binding assay,
which also employed supported lipid monolayers. It is, however,
important to note that AFM is a qualitative approach hence the
ratios of oligomer binding cannot be ascertained. AFM averages
and images reported in this study were determined from at least 6
positions per sample; scanning probe microscopy techniques do
not sample the entire surface. In contrast, SELDI is quantitative;
scans are made across the entire spot (every 5th position) and
data presented is an average of 65 transients. Employing AFM
analysis, we demonstrated that Wt α-synuclein and familial
mutants all possess the ability to perturb the lipid surface. Profilestudies of proteins associated with the lipid layer revealed
the presence of ‘small features’ consistent with the presence
of monomers and those double in size, dimers. AFM studies
using lipid bilayers as a model for cell membranes reported
similar findings; Jo et al. [36] demonstrated that the association
of α-synuclein Wt and A53T resulted in extensive lipid dis-
ruption. Further to this, Zhu et al. [13] demonstrated that both
α-synuclein Wt monomers and protofibrils (oligomers) disrupt
lipid layers, the latter of which causes more rapid disruption.
Interestingly, we noted a characteristic pattern of lipid di-
sruption surrounding the protein on the surface. We cannot
determine neither affirm at this stage if the protein is embedded
in the lipid layer, but the AFM analysis shows the protein
appeared to be pushing the lipid away in one direction, but not
surrounding the entire protein as there was no (or relatively
little) lipid disruption observed in the adjacent regions above the
protein (Fig. 6b). Based on the analysis of the primary sequence,
we postulated that the hydrophobic N-terminus buries into the
monolayer disrupting the cohesive forces of the surrounding
lipid layer, the positive residues in the N-terminus bind the
negatively charged lipids [13], whilst the acidic C-terminus ex-
hibits a charge repulsion with the negatively charged membrane
surface which “pushes” the lipid away. Interestingly a study by
Narayanan and Scarlata [37] demonstrated that changing the pH
of the binding buffer actually abrogates this charge repulsion
and leads to enhanced lipid binding.
In summary, we employed a novel SELDI-TOF MS-lipid
binding assay and AFM to assess the lipid binding profiles of
α-synuclein Wt, A53T and A30P. SELDI analysis demon-
strated that the dimeric species of α-synuclein Wt and its
familial mutants preferentially bind membranes. AFM analysis
revealed Wt and its familial mutants can penetrate lipid mem-
branes or disrupt the lipid and bind directly to the SAM used to
form the lipid layer. The profile of these studied proteins
revealed the presence of ‘small features’ consistent with the
presence of monomers and those double in size, dimers. The
information generated from this study will aid to elucidate the
role of α-synuclein in PD pathogenesis, which may provide
novel therapeutic targets.
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